Key result
Asian population aging is projected to drive a ~91% rise in cardiovascular mortality by 2050.
Why the study?
Cardiovascular disease poses a growing burden across Asia, where diverse genetic, socioeconomic, and environmental factors create substantial heterogeneity in risk profiles and outcomes, while advances in genomics, digital cardiology, and precision medicine are reshaping care.
With cardiovascular mortality in Asia projected to rise by 91% to nearly 24 million annual deaths by 2050, integrating region-specific evidence, precision medicine, and digital health with equitable access is critical.
Answers are grounded in this paper and cite their sources.
Highlights urgent need for Asia-specific cardiovascular planning amid aging; leaves open optimal mitigation strategies pending prospective studies.
Cardiovascular disease remains the leading cause of mortality worldwide and is responsible for an increasing health and economic burden across Asia. The region encompasses remarkable diversity in ethnicity, genetics, socioeconomic development, lifestyle, healthcare systems, and environmental exposures, resulting in substantial heterogeneity in cardiovascular risk profiles, disease phenotypes, and clinical outcomes. Simultaneously, advances in genomics, pharmacogenomics, artificial intelligence (AI), digital cardiology, remote monitoring, and precision medicine are reshaping contemporary cardiovascular care. This review aimed to provide a narrative review of the epidemiology, regional diversity, genetic and environmental determinants, prevention strategies, contemporary therapeutics, pharmacogenomics, digital cardiology, AI, and future directions of cardiovascular medicine in Asia. A narrative review was conducted following the principles of the Scale for the Assessment of Narrative Review Articles (SANRA). Electronic databases including PubMed/MEDLINE, Scopus, and the Cochrane Library were searched for English-language publications between January 1990 and June 2026. Clinical practice guidelines from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), Asian Pacific Society of Cardiology (APSC), World Health Organization (WHO), and national cardiovascular societies were incorporated. Priority was given to randomized controlled trials, meta-analyses, systematic reviews, consensus statements, and large population-based studies. Asia exhibits marked heterogeneity in cardiovascular disease burden driven by differences in genetics, cardiometabolic phenotype, environmental exposures, urbanization, and healthcare delivery. Precision medicine, including genomics, polygenic risk scores, pharmacogenomics, biomarkers, advanced imaging, AI, wearable technologies, and remote monitoring, offers opportunities for individualized prevention and treatment. However, significant challenges remain regarding equitable implementation, clinical validation, digital infrastructure, affordability, and workforce development. Current forecasts project that crude cardiovascular mortality in Asia will rise by approximately 91% between 2025 and 2050, approaching 24 million deaths annually, driven primarily by population aging. The future of cardiovascular medicine in Asia will depend upon integrating evidence-based clinical practice with precision medicine, implementation science, digital health, and AI while ensuring equitable access to care. Collaborative multinational research and region-specific evidence generation are essential to improve cardiovascular outcomes across Asia.
No takes yet. Share an insight, caveat, or question.
Mrinal Kanti Das (2026) conducted a review in Cardiovascular disease. Precision medicine, genomics, pharmacogenomics, digital cardiology, and artificial intelligence was evaluated on Projected crude cardiovascular mortality in Asia between 2025 and 2050. Population aging in Asia is projected to drive an approximate 91% rise in crude cardiovascular mortality between 2025 and 2050, approaching 24 million deaths annually.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: